All In Biotech

Drug Trial Radar · NCT04634877

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 990 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

990

Planned (sponsor's estimate)

Start

Jan 10, 2021

Primary completion

Nov 20, 2026

Study completion Nov 20, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT); Gynecologic Oncology Group
First posted
Nov 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS.

Conditions

  • Endometrial Neoplasms

Interventions

  • PembrolizumabBiological

    IV infusion

  • CarboplatinDrug

    IV infusion

  • PaclitaxelDrug

    IV infusion

  • Placebo for pembrolizumabDrug

    IV infusion

  • DocetaxelDrug

    IV infusion docetaxel 75 mg/m\^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.

  • CisplatinDrug

    Cisplatin 75 mg/m\^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.

  • External Beam Radiotherapy (EBRT)Radiation

    ≥4500 cGY given according to local practice, at the discretion of the investigator

  • Cisplatin (as radiosensitizer)Drug

    If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m\^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29

  • BrachytherapyRadiation

    Given according to local practice, at the discretion of the investigator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease RecurrenceTime frame: Up to approximately 42 months
  2. Overall Survival (OS)Time frame: Up to approximately 54 months

Locations

231 sites in 28 countries. Site status is shown where the registry gives one.

  • University of Alabama - Birmingham ( Site 3061)

    Birmingham, Alabama

  • University of South Alabama, Mitchell Cancer Institute ( Site 3058)

    Mobile, Alabama

  • HonorHealth Research Institute - Biltmore ( Site 3043)

    Phoenix, Arizona

  • Arizona Oncology Associates PC- HOPE ( Site 3049)

    Tucson, Arizona

  • UCSD Moores Cancer Center ( Site 3053)

    La Jolla, California

  • University Of Colorado ( Site 3051)

    Aurora, Colorado

  • Smilow Cancer Hospital at Yale New Haven ( Site 3070)

    New Haven, Connecticut

  • Mount Sinai Cancer Center ( Site 3081)

    Miami Beach, Florida

  • Northside Hospital ( Site 3036)

    Atlanta, Georgia

  • Northwestern Memorial Hospital ( Site 3044)

    Chicago, Illinois

  • Parkview Cancer Institute ( Site 3067)

    Fort Wayne, Indiana

  • Indiana University Melvin and Bren Simon Cancer Center ( Site 3071)

    Indianapolis, Indiana

  • University of Iowa Hospital and Clinics ( Site 3046)

    Iowa City, Iowa

  • Norton Cancer Institute - St. Matthews ( Site 3056)

    Louisville, Kentucky

  • WK Physicians Network/Gynecologic Oncology Associates ( Site 3047)

    Shreveport, Louisiana

  • University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 3037)

    Worcester, Massachusetts

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 3076)

    Mineola, New York

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 3042)

    New York, New York

  • Montefiore Medical Center ( Site 3065)

    The Bronx, New York

  • Duke Cancer Center ( Site 3072)

    Durham, North Carolina

  • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 3080)

    Fargo, North Dakota

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 3066)

    Columbus, Ohio

  • Legacy Good Samaritan Medical Center ( Site 3033)

    Portland, Oregon

  • Sidney Kimmel Cancer Center - Jefferson Health ( Site 3078)

    Philadelphia, Pennsylvania

  • AHN West Penn Hospital ( Site 3060)

    Pittsburgh, Pennsylvania

  • Abington Hospital - Asplundh Cancer Center ( Site 3073)

    Willow Grove, Pennsylvania

  • Sanford Gynecology Oncology ( Site 3045)

    Sioux Falls, South Dakota

  • UT Southwestern Medical Center ( Site 3063)

    Dallas, Texas

  • VCU Massey Cancer Center ( Site 3068)

    Richmond, Virginia

  • IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas ( Site 1010)

    Buenos Aires, Argentina

  • Hospital Aleman ( Site 1001)

    Buenos Aires, Argentina

  • Centro Oncologico Riojano Integral ( Site 1007)

    La Rioja, Argentina

  • Centro de Oncología e Investigación de Buenos Aires ( Site 1005)

    Berazategui, Buenos Aires, Argentina

  • IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 1006)

    CABA, Buenos Aires, Argentina

  • CEMIC ( Site 1009)

    CABA, Buenos Aires, Argentina

  • Hospital Britanico de Buenos Aires ( Site 1002)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 1003)

    Mar del Plata, Buenos Aires, Argentina

  • Instituto de Oncologia de Rosario ( Site 1004)

    Rosario, Santa Fe Province, Argentina

  • Medizinische Universitat Graz ( Site 2004)

    Graz, Styria, Austria

  • Medizinische Universitaet Innsbruck ( Site 2001)

    Innsbruck, Tyrol, Austria

Showing 40 of 231 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.